Skip to content

PCOS (Polycystic Ovary Syndrome)

Polyendocrine metabolic ovarian syndrome (PMOS), formerly called polycystic ovary syndrome (PCOS), is a common endocrine and metabolic condition with reproductive, dermatologic, psychological, and cardiometabolic features. Its presentation is heterogeneous. A person may have irregular ovulation, androgen-related symptoms, polycystic ovarian morphology, metabolic complications, fertility difficulty, or several of these without having every feature associated with the condition.

The older name is misleading. The ovarian finding consists of numerous small arrested follicles rather than abnormal ovarian cysts, and neither cysts nor a particular ultrasound appearance are required in every adult diagnosis. In May 2026, an international consensus process renamed the condition polyendocrine metabolic ovarian syndrome to reflect its systemic endocrine and metabolic effects. PCOS remained in use during a multi-year terminology transition and appears in older medical records and research.

Presentation and Daily Effects

Ovulatory dysfunction may appear as long, unpredictable, or absent menstrual cycles, although apparently regular cycles do not prove that ovulation occurs consistently. Clinical or biochemical androgen excess may produce hirsutism, acne, or androgen-related scalp hair thinning. The form and importance of these features vary with age, genetics, medication, hair-removal practices, and cultural context.

Insulin resistance is an important feature for many people but is not present or measured in the same way in everyone. PCOS can occur at any body size. Higher weight, difficulty losing weight, or rapid weight change may interact with its metabolic effects, but body size does not establish the diagnosis, and weight loss is not a prerequisite for receiving treatment.

The condition can affect energy, sleep, eating, body image, sexual wellbeing, and confidence in medical care. Depression, anxiety, eating disorders, and impaired quality of life occur more often in people with PCOS and warrant direct assessment rather than being assumed from appearance or fertility history.

Diagnosis

Adult diagnosis builds on the Rotterdam framework and requires exclusion of other explanations for the symptoms. Two of the following three features are generally required:

Clinical or biochemical hyperandrogenism.

Ovulatory dysfunction.

Polycystic ovarian morphology on ultrasound or, in adults, an elevated anti-Müllerian hormone result used in place of ultrasound under an appropriate diagnostic algorithm.

When an adult has both irregular cycles and hyperandrogenism, ultrasound and anti-Müllerian hormone testing are not required to complete the diagnosis. Anti-Müllerian hormone is not a stand-alone screening test, and the meaning of either hormone levels or ovarian morphology depends on age, laboratory method, ultrasound technology, medication, and clinical context.

Adolescent diagnosis is more restrictive because irregular cycles and multifollicular ovaries can be normal during pubertal development. Both persistent ovulatory dysfunction, defined in relation to time since menarche, and clinical or biochemical hyperandrogenism are required after other causes are excluded. Ultrasound and anti-Müllerian hormone are not recommended to diagnose PCOS in adolescents because of poor specificity.

The differential diagnosis can include pregnancy, thyroid disease, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, hypothalamic or pituitary disorders, medication effects, Cushing syndrome, androgen-secreting tumors, and ordinary pubertal transition. History and examination guide which testing is appropriate.

Health Risks and Monitoring

PCOS is associated at a population level with impaired glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, and cardiovascular risk factors. Blood pressure, glycemic status, lipids, sleep symptoms, family history, medication, and other risks are assessed individually. Routine insulin assays are not sufficiently accurate to diagnose or grade insulin resistance in ordinary clinical practice.

Long-standing untreated amenorrhea can expose the endometrium to prolonged estrogen without regular progesterone opposition. This raises the risk of endometrial hyperplasia and endometrial cancer, although the absolute cancer risk remains low and routine cancer screening is not recommended solely because of PCOS. Cycle regulation or scheduled progestogen can protect the endometrium when spontaneous cycles are infrequent.

The condition continues to matter after the reproductive years even when cycle patterns and androgen levels change. Pregnancy does not cure it. A hysterectomy removes the uterus and ends the ability to carry a pregnancy, but it does not by itself remove the ovaries or erase metabolic, androgen-related, sleep, or psychological features. Removal of one or both ovaries is a separate procedure with different consequences.

Management

Management follows the person’s priorities rather than one universal sequence. Relevant goals may include predictable bleeding, endometrial protection, acne or hair treatment, metabolic health, fertility, sleep, mental health, pain from a separate condition, or relief from weight stigma and medical dismissal.

Combined hormonal contraception is a first-line medication option for menstrual irregularity and hyperandrogenism when pregnancy is not desired and no contraindication is present. Progestogen-only regimens can provide cycle control or endometrial protection in selected situations. Anti-androgen treatment requires attention to contraception, adverse effects, and monitoring, while acne and hair concerns can also be managed with dermatologic and cosmetic options chosen by the person.

Metformin is used primarily for selected metabolic features and can also affect cycles and ovulation. It is not a universal PCOS medication, a guaranteed fertility treatment, or routine treatment throughout every PCOS pregnancy. Gastrointestinal effects, vitamin B12 status during long-term use, other health conditions, and individual goals influence whether it is appropriate.

Regular movement, adequate nutrition, sleep, and sustainable health habits can improve wellbeing and metabolic health even without weight loss. No single diet or exercise plan is uniquely effective for PCOS. Weight-focused care should be offered only with informed discussion, and clinicians should ask permission before weighing someone when a measurement is relevant.

For anovulatory infertility without another infertility factor, letrozole is the preferred first-line pharmacological ovulation-induction treatment. Clomiphene, metformin in selected combinations, gonadotropins, ovarian surgery, or in vitro fertilization may be considered according to prior response, other fertility factors, access, cost, and the risk of ovarian hyperstimulation or multiple pregnancy. PCOS does not mean that spontaneous ovulation or conception is impossible.

Pregnancy

Pregnancies in people with PCOS are considered higher risk at a population level. Research shows increased rates of miscarriage, gestational diabetes, gestational hypertension, preeclampsia, preterm birth, and some other complications. More recent register studies have also found an association with stillbirth, particularly at term, while emphasizing that causal mechanisms remain uncertain.

These associations guide preconception assessment and antenatal monitoring; they do not determine what will happen in an individual pregnancy or identify the cause of an individual loss. PCOS alone does not prove that it caused a miscarriage, stillbirth, preeclampsia, preterm delivery, or neonatal complication. It is not an established cause of hyperemesis gravidarum, and spontaneous PCOS pregnancy does not inherently produce twins. Fertility medications that stimulate ovulation can increase the chance of multiple pregnancy, while twin gestation independently increases obstetric risk.

Preconception and pregnancy care can include review of medications, blood pressure, glucose status, nutrition, sleep, mental health, folate, tobacco or substance exposure, and other health conditions. Glucose testing is recommended before pregnancy or fertility treatment when possible and early in pregnancy if it was not completed beforehand, with repeat testing later in gestation according to current guidance.

Accessibility and Medical-System Context

Care may require trauma-informed pelvic or ultrasound examinations, permission before weight discussion, gowns and equipment that fit a range of bodies, private hair and skin assessment, gender-affirming language, clear explanations of testing, and space to discuss fertility without assuming that pregnancy is desired. Transgender men and nonbinary people with relevant endocrine and reproductive anatomy can also have PCOS or PMOS.

The condition is often delayed or missed when clinicians treat irregular cycles as inconsequential, require a stereotyped body type, confuse follicles with ovarian cysts, focus only on fertility, or tell a person to lose weight before investigating symptoms. The opposite error is also possible: ovarian morphology alone can occur without the syndrome and should not replace a complete diagnostic assessment.

Historical Context

Irving Stein and Michael Leventhal’s 1935 report described amenorrhea, hirsutism, infertility, and enlarged ovaries in a small surgical series. Ovarian wedge resection became an early treatment but carried surgical and adhesion risks. Later work established the condition’s endocrine and metabolic dimensions, while ultrasound made ovarian morphology visible without surgery.

The 1990 National Institutes of Health criteria emphasized hyperandrogenism and ovulatory dysfunction. The 2003 Rotterdam consensus allowed adult diagnosis when two of three core features were present after exclusion of other causes. Later international guidelines refined cycle definitions, ultrasound thresholds, adolescent diagnosis, metabolic and psychological assessment, fertility treatment, and the adult use of anti-Müllerian hormone as an alternative to ultrasound.

The international adoption of the name PMOS in 2026 reflected both scientific change and lived experience. It rejected the implication that abnormal cysts define the condition and placed its multi-system endocrine and metabolic effects at the center of care.

Associated Characters

Ayana Brooks

Ayana was diagnosed with PCOS in adulthood. Irregular ovulation and the prognosis she received led her to believe she would probably need medical assistance to conceive. After relationships that did not become lasting partnerships, she came to believe that biological motherhood might not happen for her and did not pursue fertility treatment on her own.

Shortly after Elliot Landry completed treatment for his glioma, Ayana became pregnant without fertility intervention at approximately age forty-one or forty-two. The positive test shocked her because it contradicted the future she had learned to expect. She called Jazmine Landry, who found her trembling on the bathroom floor. Ayana told her, “It’s positive,” and then, “I think there’s more than one.”

The pregnancy involved severe hyperemesis gravidarum, dehydration, preeclampsia warning signs, bedrest, and mobility limitations. Her age, twin gestation, and PCOS all informed high-risk monitoring, but they did not make every complication inevitable or establish one condition as the sole cause. Ariana Landry and Adrian Landry were born prematurely around 2051 and required neonatal intensive care. The spontaneous pregnancy did not cure Ayana’s PCOS.

Julia Weston

Julia was diagnosed with PCOS during her undergraduate years at Harvard University. She and Nathan Weston experienced four early pregnancy losses before their pregnancy with Grace Weston reached thirty-eight weeks. Grace was stillborn on June 23, 2006, after a pregnancy with no identified warning signs; the autopsy was inconclusive, and no definitive cause was established.

In 2021, Julia read research reporting an association between PCOS and stillbirth, with the increase particularly apparent at term. The paper gave her a possible risk factor that had not been recognized in 2006, not a retrospective diagnosis or proof of why Grace died. She cried alone in the Roslyn Avenue study and sat in the dark after closing the laptop. Nathan returned from work, brought her water, and stayed beside her without demanding an explanation.

During Julia’s pregnancy with Logan Weston, her PCOS, four early losses, and Grace’s unexplained stillbirth informed close surveillance. She developed severe preeclampsia, and labor was induced at thirty-seven weeks.

Michelle Medina

Michelle was diagnosed with PCOS and hypothyroidism in her late teens. Fatigue, pain from coexisting endometriosis, weight changes, and years of weight-based bullying shaped a difficult relationship with her body. Cisco Medina helped her become more comfortable with her stretch marks, surgical scar, and full-figured build through years of consistent affection rather than treating her body as a problem to solve.

Michelle’s pregnancy with Miguel Ángel was medically difficult and included pregnancy-related hypertension that resolved after delivery. Her endometriosis was treated with a hysterectomy after his birth, making Miguel Ángel her only child. The hysterectomy was treatment for endometriosis rather than PCOS and did not automatically end the endocrine or metabolic features of PCOS. Mild hypertension returned as Michelle aged, while hypothyroidism and PCOS continued to require ongoing care.

Sources

  • [https://www.monash.edu/medicine/mchri/pcos/guideline Monash University—International Evidence-Based PMOS/PCOS Guideline]
  • [https://pmc.ncbi.nlm.nih.gov/articles/PMC10477934/ Teede et al.—Recommendations from the 2023 International Evidence-Based Guideline]
  • [https://www.monash.edu/news/articles/polyendocrine-metabolic-ovarian-syndrome-new-name-to-improve-diagnosis-and-care-of-condition-affecting-170-million-women-worldwide Monash University—Polyendocrine Metabolic Ovarian Syndrome Name Change]
  • [https://uu.diva-portal.org/smash/get/diva2%3A1531150/FULLTEXT01.pdf Valgeirsdottir et al.—Polycystic Ovary Syndrome and Risk of Stillbirth]
  • [https://pubmed.ncbi.nlm.nih.gov/39474934/ Elenis et al.—PCOS, Gestational Diabetes, and Pregnancy Outcomes]
  • [https://www.acog.org/womens-health/faqs/hysterectomy American College of Obstetricians and Gynecologists—Hysterectomy]
Medical Conditions Endocrine Disorders Reproductive Health Ayana Brooks Julia Weston Michelle Medina